MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without

Clinical Trial Summary

This is an open-label, prospective, randomized, multicenter phase II trial that will evaluate the efficacy and safety of intermittent addition of cetuximab to a FOLFIRI-based first line therapy to patients with RAS (Rat sarcoma)-mutant mCRC (Metastatic colorectal cancer) diagnosis who convert to RAS wild-type using monitoring of the RAS mutation status by liquid biopsy.

See also
Status	Clinical Trial	Phase
Completed	`NCT00025337` - Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated	Phase 3
Completed	`NCT03871959` - Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma	Phase 1
Recruiting	`NCT05080673` - Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps	N/A
Completed	`NCT01037790` - Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Phase 2
Completed	`NCT00707889` - Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer	Phase 2
Completed	`NCT00551421` - Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer	Phase 1/Phase 2
Terminated	`NCT00052585` - Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer	Phase 2
Completed	`NCT00023933` - Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer	Phase 1
Recruiting	`NCT03303547` - Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits	N/A
Active, not recruiting	`NCT01037049` - Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks	Phase 2
Terminated	`NCT00397878` - AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer	Phase 2
Completed	`NCT00100841` - Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer	Phase 2
Completed	`NCT00028496` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Phase 1
Recruiting	`NCT04005118` - Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
Completed	`NCT02641691` - Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum	Phase 2
Completed	`NCT00307736` - Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer	Phase 1/Phase 2
Completed	`NCT00003799` - Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer	Phase 1
Terminated	`NCT00303628` - Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer	Phase 3
Terminated	`NCT02425683` - Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX	Phase 2
Recruiting	`NCT05669430` - A Study of GV20-0251 in Patients With Solid Tumor Malignancies	Phase 1

NCT number	NCT04554836
Study type	Interventional
Source	TheraOp
Contact
Status	Active, not recruiting
Phase	Phase 2
Start date	December 29, 2020
Completion date	October 1, 2024

MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms